Literature DB >> 32682869

Treatment of Multiple Sclerosis: A Review.

Stephen L Hauser1, Bruce A C Cree2.   

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-cell therapy; MS therapy; Multiple sclerosis

Mesh:

Substances:

Year:  2020        PMID: 32682869      PMCID: PMC7704606          DOI: 10.1016/j.amjmed.2020.05.049

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  67 in total

1.  Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.

Authors:  Robert H Scannevin; Sowmya Chollate; Mi-young Jung; Melanie Shackett; Hiral Patel; Pradeep Bista; Weike Zeng; Sarah Ryan; Masayuki Yamamoto; Matvey Lukashev; Kenneth J Rhodes
Journal:  J Pharmacol Exp Ther       Date:  2012-01-20       Impact factor: 4.030

Review 2.  Multiple sclerosis: current knowledge and future outlook.

Authors:  Christian P Kamm; Bernard M Uitdehaag; Chris H Polman
Journal:  Eur Neurol       Date:  2014-07-30       Impact factor: 1.710

3.  Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.

Authors:  Paul Browne; Dhia Chandraratna; Ceri Angood; Helen Tremlett; Chris Baker; Bruce V Taylor; Alan J Thompson
Journal:  Neurology       Date:  2014-09-09       Impact factor: 9.910

4.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin
Journal:  Lancet Neurol       Date:  2014-03-28       Impact factor: 44.182

5.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

6.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Authors:  Ludwig Kappos; Amit Bar-Or; Bruce A C Cree; Robert J Fox; Gavin Giovannoni; Ralf Gold; Patrick Vermersch; Douglas L Arnold; Sophie Arnould; Tatiana Scherz; Christian Wolf; Erik Wallström; Frank Dahlke
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

7.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Authors:  Jeffrey A Cohen; Giancarlo Comi; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Vivian Huang; Ludwig Kappos
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

8.  Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.

Authors:  Ludwig Kappos; Helmut Butzkueven; Heinz Wiendl; Timothy Spelman; Fabio Pellegrini; Yi Chen; Qunming Dong; Harold Koendgen; Shibeshih Belachew; Maria Trojano
Journal:  Mult Scler       Date:  2017-05-30       Impact factor: 6.312

9.  Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

Authors:  Alice Laroni; Davide Brogi; Vincenzo Brescia Morra; Leonello Guidi; Carlo Pozzilli; Giancarlo Comi; Alessandra Lugaresi; Renato Turrini; Debora Raimondi; Antonio Uccelli; Giovanni Luigi Mancardi
Journal:  BMC Neurol       Date:  2014-04-01       Impact factor: 2.474

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

View more
  66 in total

Review 1.  Peripheral nervous system in multiple sclerosis-understanding the involvement via autonomic nervous system.

Authors:  Ivan Adamec; Magdalena Krbot Skorić; Mario Habek
Journal:  Neurol Sci       Date:  2021-05-25       Impact factor: 3.307

2.  Dopaminergic Receptors as Neuroimmune Mediators in Experimental Autoimmune Encephalomyelitis.

Authors:  E C D Gonçalves; V Lieberknecht; V V Horewicz; B D Rabelo; F A Felipetti; A L S Rodrigues; D F Martins; R C Dutra
Journal:  Mol Neurobiol       Date:  2021-08-25       Impact factor: 5.590

3.  Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.

Authors:  Katarzyna Śladowska; Paweł Kawalec; Przemysław Holko; Oktawia Osiecka
Journal:  Neurol Sci       Date:  2022-06-17       Impact factor: 3.830

Review 4.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 5.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

6.  Cornuside alleviates experimental autoimmune encephalomyelitis by inhibiting Th17 cell infiltration into the central nervous system.

Authors:  Rongbo Zhang; Jin Liu; Bin Xu; You Wu; Shunli Liang; Qiang Yuan
Journal:  J Zhejiang Univ Sci B       Date:  2021-05-15       Impact factor: 3.066

7.  Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  Felipe Papa Pellizoni; Aline Zazeri Leite; Nathália de Campos Rodrigues; Marcelo Jordão Ubaiz; Marina Ignácio Gonzaga; Nauyta Naomi Campos Takaoka; Vânia Sammartino Mariano; Wellington Pine Omori; Daniel Guariz Pinheiro; Euclides Matheucci Junior; Eleni Gomes; Gislane Lelis Vilela de Oliveira
Journal:  Int J Environ Res Public Health       Date:  2021-04-27       Impact factor: 3.390

8.  Integrated analysis of differentially expressed genes and a ceRNA network to identify hub lncRNAs and potential drugs for multiple sclerosis.

Authors:  Tianfeng Wang; Si Xu; Li Liu; Shuang Li; Huixue Zhang; Xiaoyu Lu; Xiaotong Kong; Danyang Li; Jianjian Wang; Lihua Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

9.  Is there an association between multiple sclerosis and osteoarthritis in Germany? A retrospective cohort study of 8,600 patients from Germany.

Authors:  Louis Jacob; Lee Smith; Ai Koyanagi; Josep Maria Haro; Marcel Konrad; Christian Tanislav; Karel Kostev
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-06-28

10.  Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity.

Authors:  Klaus Berek; Gabriel Bsteh; Michael Auer; Franziska Di Pauli; Astrid Grams; Dejan Milosavljevic; Paulina Poskaite; Christine Schnabl; Sebastian Wurth; Anne Zinganell; Thomas Berger; Janette Walde; Florian Deisenhammer; Harald Hegen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.